Abstract. Interleukin (IL)-18 plays an important role in the pathogenesis of several liver diseases as well as Fas-mediated apoptosis. However, the effects of IL-18 on Fas-mediated liver injury have not been well elucidated. Therefore, we examined the effects of IL-18 on Fas-mediated apoptosis in in vitro and in vivo experiments. We found that recombinant IL-18 protected mouse hepatocellular carcinoma cell lines, BNL5, from Fas-mediated apoptosis in a dose-dependent manner with up-regulation of both nuclear factor (NF) $\kappa B$ and X-linked inhibitors of apoptosis (XIAP). IL-18 transgenic (Tg) mice were also protected from Fas-mediated liver injury and this was further confirmed by histological study and TUNEL staining. In IL-18 Tg mice, up-regulation of XIAP and down-regulation of caspase 3 were observed after injection of anti-Fas, which was consistent with the in vitro findings. These results suggest that IL-18 suppresses Fas-mediated apoptosis of hepatocytes by up-regulation of NF$\kappa B$ and XIAP, following inhibition of caspase-3 activity. This observation raises the possibility that IL-18 could be a therapeutic strategy for Fas-mediated liver injury as a negative regulator of XIAP.

Introduction

Interleukin (IL)-18 is a unique cytokine which has biphasic function in immune response. IL-18 stimulates Th1-mediated immune response, which plays a critical role in the host defense against infection with intracellular microbes (1). IL-18 augments NK activity through the induction of constitutively expressed IL-18 receptor on NK cells (2). IL-18 inhibited HBV replication by IFN-γ production from intrahepatic NK and NKT cells (3). IL-18 also exhibited a major protective role in mice models of herpes simplex infection (4) or vaccinia virus infection (5). On the other hand, IL-18 induced naïve T cells to develop into Th2 cells in combination with IL-4 (6). With respect to the above, discussion focused mainly on the immunological roles of IL-18. Clinically, IL-18 is involved in several liver diseases including fulminant hepatitis, viral liver cirrhosis and primary biliary cirrhosis (7). However, the effects of IL-18 on Fas-mediated liver injury have not been fully elucidated. Fas-mediated apoptosis has been implicated in several liver diseases as hepatocytes constitutively express Fas and are highly sensitive to stimulation on Fas receptor (10,11). Since IL-18 is a potent inducer of NFkB (12), which acts as an anti-apoptotic factor, IL-18 may affect apoptosis to some extent. IL-18, which has a similar biological function to IL-18, protected mice from Fas-mediated liver injury through the suppression of caspase-3-like activity (13). Furthermore, recombinant IL-18 suppressed etoposide-induced apoptosis in HCC cells (14). From this evidence, we hypothesized that IL-18 has a potential protective mechanism against Fas-mediated liver injury.

In the current study, we demonstrated that Fas-mediated apoptosis was significantly inhibited in IL-18 transgenic (Tg) mice in comparison with C57BL/6 mice. Furthermore, we found that the anti-apoptosis mechanism of IL-18 appears to be up-regulation of X-linked inhibitors of apoptosis (XIAP) through up-regulation of NFkB.

Materials and methods

Cell line. A mouse hepatocellular carcinoma cell line, BNL5, was cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum.

Animals. Male C57BL/6 mice (8-12 wks) were purchased from SLC (Shizuoka, Japan) and maintained under conditions of controlled temperature and light with free access to food.
and water. The IL-18 Tg mouse is a keratin-14 promoter driven IL-18 transgenic mouse that constitutively secretes a mature form of IL-18 in the epidermis. IL-18 Tg show marked lichenification, and severe itchy dermatitis along with massive skin infiltration of lymphocytes, mast cells, and neutrophils. Plasma IL-18, IgE, and histamine levels are markedly elevated and thus they are considered mouse models of atopic dermatitis. Skin irritation along with severe scratching is commonly observed after the age of 6 months under specific pathogen-free (SPF) conditions without differences among mice (6). Age- and sex-matched C57/BL6 mice were used as control animals. IL-18 Tg mice were backcrossed against C57BL/6 mice more than 10 generations. All animals received humane care according to the institute’s guidelines. For Fas-mediated liver injury, mice were intravenously injected with 0.25 μg/body weight (g) of anti-Fas (anti-CD95) (BD Bioscience, San Jose, CA) in 200 μl of PBS. Blood samples were taken by retro-orbital puncture 6 h after injection.

Reagents. Anti-cleaved caspase-3 (Asp175) (R&D Systems, Inc., Minneapolis, MN), anti-human IAP-like protein (hIAP)/X-linked inhibitor of apoptosis protein (XIAP), FITC-anti-Fas and FITC-anti-immunoglobulin G were purchased from BD Bioscience. FITC-anti-Fas ligand was purchased from Medical and Biological Laboratories Co. (Nagoya, Japan). Recombinant mouse IL-18 was purchased from MBL (Nagoya, Japan).

Detection of apoptosis. To assess viability of the BNL5 cells, 3-[(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was performed. BNL5 cells were seeded at a density of 1x10^4 cells/well in a 96-well microtiter plate. BNL5 cells were cultured with various concentrations of rIL-18 for 1 h. Nuclear extracts of cells were obtained by mini-nuclear extract protocol as previously reported (15). NFκB activity in the nucleus was determined by NFκB Detection Kit (Chemicon International, Temecula, CA) according to the manufacturer's protocol. Anti-cleaved caspase-3 antibody was used to detect caspase-3 activation in the nucleus. The sections were deparaffinized and digested by proteinase K and then dissolved with 500 μl of radio-immuno-precipitation assay (RIPA) buffer. Each extract was separated by 10% sodium dodecyl sulfate-polyacrylamide gradient gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. After blocking, the membrane was incubated with anti-cleaved caspase-3 (1:1,000) or anti-hILP/XIAP (1:500) at 4˚C overnight. Anti-α-tubulin (Calbiochem, San Diego, CA) was used as an internal control. The proteins were detected using electrochemiluminescence techniques (Pierce Chemicals, Rockford, IL).

The expression of FAS and FasL on hepatocytes. Livers from C57BL/6 or IL-18 Tg mice were pressed through a 70-μm cell strainer (Becton Dickinson, NJ) and washed once with ice-cold RPMI. Hepatocytes were obtained by centrifugation at 420 rpm for 5 min and were subject to Fas or FasL staining (FITC-conjugated anti-Fas or FasL antibody, BD Bioscience). All analyses were performed on a fluorescence-activity cell sorter (FACS) caliber cytometer (Becton Dickinson).

Statistical analysis. Statistical analysis was performed by Student's t-test. P-values less than 0.05 were considered significant.

Results

Recombinant IL-18 protects BNL5 cells from Fas-mediated apoptosis. Fas-mediated apoptosis in BNL5 cells was inhibited by rIL-18 in a dose-dependent manner (Fig. 1A). On the other hand, 10 ng/ml rIL-18 enhanced NFκB activity in the nucleus of BNL5 cells and NFκB in the nucleus showed a peak at 0.5 h after administration (Fig. 1B). NFκB in the BNL5 cells increased in a dose-dependent manner and showed a peak at 10 ng/ml of rIL-18 (Fig. 1C). XIAP expression was increased by rIL-18 and showed a peak at 10 ng/ml of rIL-18 (Fig. 1D). Thus, rIL-18 protected BNL5 cells from apoptosis and up-regulated NFκB and XIAP expression in the BNL5 cells.

Inhibition of Fas-mediated liver injury in IL-18 Tg mice. We attempted to ascertain whether IL-18 Tg mice were protected from Fas-mediated apoptosis. First, we confirmed that serum IL-18 levels in IL-18 Tg were significantly higher...
than those in the C57BL/6 mice before anti-Fas treatment (Fig. 2A). Six hours after injection of anti-Fas, serum ALT levels were markedly increased in C57BL/6 mice whereas serum ALT levels were significantly lower in the IL-18 Tg mice (Fig. 2B). These differences were also observable in the gross appearance of the liver surface with the liver color turning dark red and evident swelling in the C57BL/6 mice, whereas these changes were mild in IL-18 Tg mice (Fig. 2C). The changes were also confirmed by histological examination. Gross hemorrhagic hepatic necrosis was observed in the C57BL/6 mice (Fig. 2Da) whereas it was much less evident in the IL-18 Tg mice (Fig. 2Db). These differences were further corroborated by TUNEL staining (Fig. 2Dc and d). The number of TUNEL-positive cells was significantly lower in the IL-18 Tg mice than in the C57BL/6 mice (Fig. 2E). These results indicate that Fas-mediated apoptosis in the liver was significantly inhibited in the IL-18 Tg mice in comparison with the C57BL/6 mice.

**Discussion**

In this study, we examined the effects of IL-18 on Fas-mediated apoptosis. We found that IL-18 Tg mice were protected from Fas-mediated liver injury through up-regulation of the anti-apoptotic pathway, and this was further confirmed by in vitro experiments.

IL-18 plays an important role in immunological response and is related to various liver diseases. In this study, we
focused on IL-18 as an anti-apoptotic factor, and we examined the relation between IL-18 and Fas-mediated apoptosis. We demonstrated that rIL-18 inhibited the Fas-mediated apoptosis of BNL5 cells in a dose- and time-dependent manner. Furthermore, the expression of NFκB and

Figure 2. (A) Serum IL-18 levels were significantly higher in IL-18 Tg mice than in C57BL/6 mice (p<0.0001). (B) Serum ALT levels after injection of anti-Fas were significantly lower in IL-18 Tg mice than in C57BL/6 mice (p<0.05). (C) Gross appearance of liver in IL-18 Tg and C57BL/6 mice after injection of anti-Fas antibody. Liver color turned dark red and swelling was evident in the C57BL/6 mice whereas these changes were very mild in the IL-18 Tg mice. (D) Hematoxylin and eosin staining in the C57BL/6 (a) and the IL-18 Tg (b) mice after injection of anti-Fas. TUNEL staining in the C57BL/6 (c) and the IL-18 Tg (d) mice after injection of anti-Fas. (E) The number of TUNEL-positive cells was significantly lower in the IL-18 Tg mice than in the C57BL/6 mice.

Figure 3. Fas and FasL expression on hepatocytes. The expression levels of both Fas and FasL on hepatocytes were similar in the IL-18 Tg and the C57BL/6 mice (IgG anti-Fas or anti FasL).

Figure 4. Apoptotic protease expression in C57BL/6 and IL-18 Tg mice after injection of anti-Fas. The expression level of cleaved caspase-3 was significantly reduced in IL-18 Tg mice with up-regulation of XIAP in comparison with the C57BL/6 mice (representative data of two mice from each group shown).
XIAP in BN5L cells were up-regulated by rIL-18. These up-regulations may result in the protection of BN5L cells from apoptosis since they are upstream of caspase-3 and down-regulate caspase-3. Previous studies suggested that NFκB regulated XIAP gene expression, resulting in protection from tumor necrosis factor (TNF-α)-induced apoptosis (16), which is consistent with our results. It is well known that the activation of NFκB is found to block the activation of caspase through the inhibitors of apoptosis (IAP) family (17). Therefore, we examined XIAP expression in our model. After injection of anti-Fas antibody in IL-18 Tg mice, Fas-mediated liver injury was remarkably suppressed relative to C57BL/6 mice. In addition, the expression level of cleaved caspase-3 was significantly reduced in IL-18 Tg mice with up-regulation of XIAP in comparison with the C57BL/6 mice.

A previous study suggested that IL-18 Tg mice showed hepatocyte apoptosis without any treatment through spontaneous activation of the Fas pathway, as well as swollen livers (18). However, in our study, no ALT elevation was observed in IL-18 Tg mice without any treatment, and liver weight per body weight was similar to C57BL/6 mice (data not shown). On the contrary, anti-apoptotic effects against anti-Fas were observed in our IL-18 Tg mice. These differences may result from genetic differences between the two Tg mice. Serum IL-18 level in IL-18 Tg mice in the above-mentioned study was half that in our IL-18 Tg mice, which may also be a factor.

In other studies, IL-18 up-regulated functional FasL expression in NK cells (19), T cells (20) and a human hepatocellular carcinoma cell line (21). In this case, the anti-apoptotic effects in our study may result from up-regulation of FasL. Therefore, we analyzed Fas and FasL expression using hepatocytes from the C57BL/6 or the IL-18 Tg mice before any treatment. However, Fas or FasL expression on the hepatocytes was similar in C57BL/6 and IL-18 Tg mice. NFκB has been shown to play an important role in the survival and regeneration of hepatocytes (22). NFκB knock-out mice exhibit massive apoptosis of the hepatocyte, resulting in embryonic lethality (23). In this study, we demonstrated a dose-dependent and a time-dependent up-regulation of NFκB by recombinant IL-18 in the BN5L cells. Furthermore, in the IL-18 Tg mice, NFκB expression was up-regulated compared to wild mice during hepatic injury. Since NFκB stimulates the expression of anti-apoptotic molecules, we examined XIAP expression. In the IL-18 Tg mice, the expression level of XIAP was up-regulated. Thus, in IL-18 Tg mice, Fas-mediated liver injury was protected by inhibiting caspase-3 activity. In HCC cell lines, NFκB activity and the expression of XIAP mRNA were increased by treatment with recombinant human IL-18 (14). Furthermore, in IL-18 Tg mice, the NFκB levels of hepatocytes were increased (18), which is consistent with our results. In this experimental model, the same mechanism may contribute to the inhibition of Fas-mediated liver injury in the IL-18 Tg mice. Anti-apoptotic effects of IL-18, which has a similar biological function to IL-18, in Fas-mediated liver injury (13) or anti-apoptotic effect of IL-18 in hepatocellular carcinoma (14) have previously been reported. These findings suggest the protective role of IL-18 against apoptosis and potential therapeutic use of IL-18 for several liver diseases.

On the other hand, IL-18 has also induced apoptosis in human cardiac microvascular endothelial cells (12). The action of IL-18 could thus be controversial or have organ-dependent mechanisms and this should be taken into account for clinical applications.

In conclusion, IL-18 has an anti-apoptotic effect through the up-regulation of NFκB, and subsequently suppresses XIAP and caspase-3 evidenced by both in vitro and in vivo study. From our findings, IL-18 may serve as a negative regulator of apoptosis, and IL-18 itself or stimulators of the IL-18 pathway could be useful therapeutic options against several liver diseases in the future.

References

1. Sugihara I: Interleukin-18 (IL-18) and infectious disease, with special emphasis on disease induced by intracellular pathogen. Microbes Infect 2: 1257-1263, 1999.


